microRNA-935 is reduced in non-small-cell lung cancer tissue, is linked poor outcome, and acts on signal transduction mediator E2F7 and the AKT pathway.

microRNA-935 is reduced in non-small-cell lung cancer tissue, is linked poor outcome, and acts on signal transduction mediator E2F7 and the AKT pathway. Br J Biomed Sci. 2018 Sep 11; Authors: Wang C, Li S, Xu J, Niu W, Li S Abstract BACKGROUND: A potential role for microRNA-935 (miR-935) has been identified in several cancers but not in non-small cell lung cancer (NSCLC). We hypothesised changes in miR-935 in NSCLC, and proposed mechanisms that may further explain its role in carcinogenesis. METHODS: NCSLC tissue and nearby normal tissue was obtained from 101 patients and was probed by qRT-PCR for miR-935 expression. The role of miR-935 and a potential target (signal transduction factor E2F7) was determined in cell lines by a dual luciferase assay. The function of miR-935 was investigated through metabolic activity (MTT) and transwell migration assays. Western blot and immunocytochemical assays examined protein expression level. Growth of miR-935 transfected or untransfected cells was measured via xenograft tumour formation. RESULTS: miR-935 was reduced in cancer tissue and was related to lymph node metastases, TNM status and poor prognosis (all p
Source: British Journal of Biomedical Science - Category: Laboratory Medicine Tags: Br J Biomed Sci Source Type: research

Related Links:

Several anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors have been developed for the treatment of EML4-ALK-rearranged non-small-cell lung cancer, with the newer generation agents brigatinib, alectinib and lorlatinib showing pronounced central nervous system activities. Intracranial efficacy is an important feature for these agents, as metastatic lesions frequently occur in the central nervous system in the ALK-positive setting. Here, we report on an updated case of a patient who received her diagnosis in 2005 and has had disease progression with new lesions on six occasions over the last 8 years. During the firs...
Source: Anti-Cancer Drugs - Category: Cancer & Oncology Tags: Case Reports Source Type: research
Authors: Wei Z, Li Q, Ye X, Yang X, Huang G, Li W, Wang J, Han X Abstract Objective: To evaluate the efficacy of microwave ablation (MWA) and MWA plus monochemotherapy in elderly patients with advanced non-small-cell lung cancer (NSCLC). Material and methods: Patients with advanced NSCLC aged ≥70 years were retrospectively enrolled. MWA was performed at the primary tumor site. The end points included progression-free survival (PFS), response to MWA and overall survival (OS). Results: Fifty-four patients were enrolled; of these, 36 received monochemotherapy. Complete ablation was achieved in 42 patients (7...
Source: Minimally Invasive Therapy and Allied Technologies - Category: Surgery Tags: Minim Invasive Ther Allied Technol Source Type: research
ConclusionsThe efficacy of crizotinib in patients with advanced NSCLC is related to the number of metastatic organs, age and timing of treatment. The use of crizotinib is prone to intracranial progression, and progression of simple brain metastases is not an indication that crizotinib is discontinued. Patients will continue to benefit from combination of local radiotherapy.
Source: Pathology Research and Practice - Category: Pathology Source Type: research
Since the discovery of the fact that tyrosine kinase inhibitors could improve progression-free survival for patients with advanced non-small cell lung cancer compared with traditional chemotherapy, it has been extremely important to identify epidermal growth factor receptor mutation status in treatment stratification. Although lack of sufficient biopsy samples limit the precise detection of epidermal growth factor receptor mutation status in clinical practice, and it is difficult to identify the sensitive patients who confer favorable response to tyrosine kinase inhibitors. An increasing number of scholars tried to deal wi...
Source: Nuclear Medicine Communications - Category: Nuclear Medicine Tags: Review Article Source Type: research
Source: eLife - Category: Biomedical Science Tags: Biochemistry and Chemical Biology Cancer Biology Source Type: research
Worldwide, especially in China, lung cancer accounts to a major cause of mortality related to cancer. Treatment decisions mainly depend on oncogenic driver mutations, which offer novel therapeutic targets for anticancer therapy. However, studies of genomic profiling of driver gene mutations in mainland China are rare. Hence, this is an extensive study of these mutations in Non-small-cell lung cancer (NSCLC) Chinese patients. Comparison of driver gene mutations of lung adenocarcinoma with other races showed that the mutational frequencies were similar within the different East Asian populations, while there were differences...
Source: Frontiers in Genetics - Category: Genetics & Stem Cells Source Type: research
ConclusionsWe review the literature on pericardial effusion under nivolumab to further discuss the hallmarks of pericardial effusion under nivolumab and the management of nivolumab therapy in this situation. In conclusion, pericardial effusion as an immune-related adverse event under nivolumab appears less rare than initially thought and may require particular attention.
Source: Journal for Immunotherapy of Cancer - Category: Cancer & Oncology Source Type: research
Immune checkpoint blockade (ICB) using anti-PD1 [1,2] or anti-PD-L1 antibodies [3,4] has demonstrated enhanced response rates, progression free survival (PFS), and overall survival (OS) in non-small cell lung cancer (NSCLC) patients. However, only a subset of patients achieve durable clinical benefit. Since these therapies are associated with immune-related adverse events and have significant financial implications [5,6], a need exists for robust predictive biomarkers.
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
In this study, we constructed bioconjugates of targeting immune checkpoint B7 −H3 antibody and chlorin e6 to treat non-small cell lung cancer under the guidance of spectroscopic photoacoustic and fluorescence imaging.... The content of this RSS Feed (c) The Royal Society of Chemistry
Source: RSC - Chem. Commun. latest articles - Category: Chemistry Authors: Source Type: research
Authors: Weng X, Luo S, Lin S, Zhong L, Li M, Xin R, Huang P, Xu X Abstract To evaluate the cost-utility of pembrolizumab versus chemotherapy as the first-line setting for metastatic non-small cell lung cancer (NSCLC) from the US health care system perspective. A Markov model was developed to compare the life-time cost and effectiveness of pembrolizumab versus chemotherapy for untreated metastatic NSCLC, based on the clinical data derived from phase III randomized controlled trial (KEYNOTE-042, ClinicalTrials.gov, NCT02220894). Weibull distribution was fitted to simulate the parametric survival functions. Drug cost...
Source: Oncology Research - Category: Cancer & Oncology Tags: Oncol Res Source Type: research
More News: Biomedical Science | Cancer | Cancer & Oncology | Laboratory Medicine | Lung Cancer | Non-Small Cell Lung Cancer | Science | UK Health